Empagliflozin and Major Renal Outcomes in Heart Failure.

Published on Aug 27, 2021in The New England Journal of Medicine74.699
· DOI :10.1056/NEJMC2112411
Milton Packer120
Estimated H-index: 120
(Baylor University Medical Center),
Javed Butler99
Estimated H-index: 99
(University of Mississippi)
+ 8 AuthorsChristoph Wanner19
Estimated H-index: 19
(University of Würzburg)
Sources
Abstract
Empagliflozin and Renal Outcomes in Heart Failure In a planned pooled analysis of two trials that evaluated empagliflozin in patients with heart failure, major adverse renal outcomes occurred in 2....
📖 Papers frequently viewed together
2021
202123.60Circulation
13 Authors (Faiez Zannad, ..., Milton Packer)
34 Citations
3 Citations
References0
Newest
Cited By4
Newest
#1Pierre Delanaye (University of Liège)H-Index: 49
#2André Scheen (University of Liège)H-Index: 93
Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering agents that provide cardiovascular and renal protection in both patients with and without type 2 diabetes. Because of their unique mechanism of action, increased glucosuria is associated with osmotic diuresis and some natriuresis, yet the latter seems mostly transient. The potential role of the diuretic effect in overall cardiovascular and renal protection by SGLT2is remains a matter of debate. Precise evaluat...
1 CitationsSource
#1Gianluigi Savarese (Karolinska University Hospital)H-Index: 30
#2Lars H. Lund (Karolinska University Hospital)H-Index: 70
Last. Andrew J.S. Coats (Warw.: University of Warwick)H-Index: 140
view all 4 authors...
Source